![]() |
|
|
Vol. 283, Issue 3, 1453-1459, 1997
Biochemical Pharmacology, University of Konstanz, Konstanz, Germany
(S.U., R.L.F., H.-D.H., A.W.);
Byk Gulden, Ltd., Konstanz, Germany
(C.S.); and
Medical Center of Pediatrics, University Hospital Marburg,
Marburg, Germany (R.N.)
Exposure of perfused rat lungs to lipopolysaccharides (LPS)
causes induction of cyclooxygenase-2 followed by thromboxane
(TX)-mediated bronchoconstriction (BC). Recently, phosphodiesterase
(PDE) inhibitors have received much interest because they not only are
bronchodilators but also can suppress release of proinflammatory
mediators. In the present study, we investigated the effect of three
different PDE inhibitors on TX release and BC in LPS-exposed perfused
rat lungs. The PDE inhibitors used were motapizone (PDE III specific), rolipram (PDE IV specific), and zardaverine (mixed PDE III and IV
specific). At 5 µM, a concentration at which all three compounds selectively block their respective PDE isoenzyme, rolipram
(IC50 = 0.04 µM) and zardaverine (IC50 = 1.8 µM) largely attenuated the LPS-induced BC, whereas motapizone was
almost ineffective (IC50 = 40 µM). In contrast to LPS, BC
induced by the TX-mimetic U46619 was prevented with comparable strength
by motapizone and rolipram. In LPS-treated lungs, the TX release was
reduced to 50% of controls by rolipram and zardaverine but was
unaltered in the presence of 5 µM motapizone. Increasing
intracellular cAMP through perfusion of db-cAMP or forskolin (activates
adenylate cyclase) also reduced TX release and BC. We conclude that PDE inhibitors act via elevation of intracellular cAMP.
Although both PDE III and PDE IV inhibitors can relax airway smooth
muscle, in the model of LPS-induced BC, PDE IV inhibitors are more
effective because (in contrast to PDE III inhibitors) they also
attenuate TX release.
This article has been cited by other articles:
![]() |
R.T. Schermuly, H. Leuchte, H.A. Ghofrani, N. Weissmann, F. Rose, M. Kohstall, H. Olschewski, C. Schudt, F. Grimminger, W. Seeger, et al. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure Eur. Respir. J., August 1, 2003; 22(2): 342 - 347. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Toward and K. J. Broadley Goblet Cell Hyperplasia, Airway Function, and Leukocyte Infiltration after Chronic Lipopolysaccharide Exposure in Conscious Guinea Pigs: Effects of Rolipram and Dexamethasone J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 814 - 821. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Toward and K. J. Broadley Chronic Lipopolysaccharide Exposure on Airway Function, Cell Infiltration, and Nitric Oxide Generation in Conscious Guinea Pigs: Effect of Rolipram and Dexamethasone J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 298 - 306. [Abstract] [Full Text] |
||||
![]() |
M. Aoki, S. Yamamoto, M. Kobayashi, K. Ohga, H. Kanoh, K. Miyata, K. Honda, and T. Yamada Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 165 - 173. [Abstract] [Full Text] |
||||
![]() |
M. Ermert, M. Merkle, R. Mootz, F. Grimminger, W. Seeger, and L. Ermert Endotoxin priming of the cyclooxygenase-2-thromboxane axis in isolated rat lungs Am J Physiol Lung Cell Mol Physiol, June 1, 2000; 278(6): L1195 - L1203. [Abstract] [Full Text] [PDF] |
||||